-

Blackstone Real Estate Debt Strategies Launches Homebuilder Lending Platform

Expects to Support Construction of over 50,000 New Homes Annually

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE: BX) today announced that Blackstone Real Estate Debt Strategies (“BREDS”) has launched a lending platform that will provide much needed capital and flexibility to homebuilders, and expects to enable the construction of over 50,000 for-sale homes across the United States annually.

This lending platform is supported by BREDS portfolio company, Brio Homebuilder Solutions, as well as partnerships with third parties. This commitment comes at a time when the U.S. is facing a critical housing shortage. Fewer homes are being built today than in 1960, despite the U.S. population nearly doubling.

Tim Johnson, Global Head of Blackstone Real Estate Debt Strategies, said: "America needs more homes, and we are proud to be part of the solution. Our homebuilder lending platform will help deliver thousands of new homes across the United States, directly addressing the critical housing supply gap in communities where people want to live.”

This platform builds on Blackstone Real Estate’s longstanding commitment to providing high-quality, affordable housing. Tricon Residential, a Blackstone Real Estate portfolio company, has developed or is developing ~64,000 single-family homes and home sites. Blackstone Real Estate’s affordable housing portfolio company, April Housing, is on track to be the largest preserver of affordable housing in 2026. Together with Blackstone, April Housing has already preserved the affordability of over 3,000 apartments and invested over $300 million to improve its communities through its newly launched resyndication program.

About Blackstone Real Estate Debt Strategies
Blackstone Real Estate Debt Strategies (“BREDS”) is the largest alternative asset manager of real estate credit with $78 billion of investor capital under management. Serving institutional, insurance, and individual investors, BREDS originates loans and makes debt investments across global private and public real estate credit markets and across the capital structure and risk spectrum. BREDS also manages Blackstone Mortgage Trust (NYSE: BXMT), a publicly-traded commercial mortgage REIT, and is a fully integrated part of the Blackstone Real Estate platform, the largest owner of commercial real estate globally.

Contacts

Blackstone
Claire Keyte
Claire.Keyte@Blackstone.com

Blackstone

NYSE:BX

Release Versions

Contacts

Blackstone
Claire Keyte
Claire.Keyte@Blackstone.com

More News From Blackstone

The AI-Native Enterprise Services Firm Backed by Anthropic, Blackstone, and Hellman & Friedman Announces Acquisition of Fractional AI

SAN FRANCISCO--(BUSINESS WIRE)--The recently announced AI-native enterprise services firm led by Anthropic, Blackstone, Hellman & Friedman, and others to help mid-size companies bring Claude into their core operations, today announced the acquisition of Fractional AI, a leading applied AI services company based in San Francisco. Fractional AI’s team and delivery capabilities will serve as the founding operational centerpiece of the new company. Fractional AI was founded in 2024 by Chris Tay...

Blackstone Announces Joint Venture with Google to Create New TPU Cloud

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE: BX) today announced a joint venture with Google to create a new U.S.-based company that will offer efficient data center capacity, operations, networking, and Google Cloud's Tensor Processing Units (TPUs) as a compute-as-a-service offering. The company will give customers another option to access cloud TPUs in addition to using them through Google Cloud. Google’s TPUs are custom chips purpose-built for AI, and optimized for training and inference of...

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency

NEW YORK & NATICK, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a $250 million investment in Anagram Therapeutics (“Anagram”), a clinical-stage private biopharmaceutical company dedicated to improving the lives of people living with exocrine pancreatic insufficiency due to cystic fibrosis (“CF”), pancreatic cancer and related disorders. The investment will help fund the further development, approval and launch of Anagram’s ANG003, a novel orally delivered recombinan...
Back to Newsroom